Medulloblastoma
Transplant advances and outcomes
Medulloblastoma is the most common malignant brain tumor in the pediatric population. Advanced studies of this complex cancer's biology have led to defined treatment regimens and clinical trials involving autologous HCT.
Recommended timing for transplant consultation
High-dose therapy with autologous stem cell support may be considered standard therapy for several infant (younger than 3 years of age) embryonal tumors as first line, including:
- Medulloblastoma
- Atypical teratoid rhabdoid tumor (AT/RT)
- Embryonal tumor with multilayered rosettes (ETMR)
- Primitive neuroectodermal/embryonal tumors, not otherwise specified (NOS)
High-dose therapy with autologous stem cell support may be considered at relapse for patients with:
- Embryonal tumors if the patient has chemoresponsive disease to re-induction chemotherapy and does not have bulky residual disease
References
- Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. Journal of neurosurgery Pediatrics. 2019;24(4):353-363. doi:10.3171/2019.5.PEDS18381. Access